DealZone

Deals wrap: Key facts about the Sanofi/Genzyme deal

February 16, 2011

Chris Viehbacher, CEO of Sanofi-Aventis, gestures as he speaks during a news conference to present Sanofi-Aventis' 2010 annual results in Paris February 9, 2011.   REUTERS/Charles Platiau  French drugmaker Sanofi-Aventis agreed to buy Genzyme with a sweetened $20.1 billion cash offer, plus payments tied to the success of the U.S. biotech group’s drugs, the companies said. Reuters has a factbox about the two companies, a timeline of Sanofi’s quest for Genzyme and a look at Sanofi’s patient CEO.

The London Stock Exchange’s bid to take over Canada’s TMX GroupĀ  is likely to navigate through a battery of regulatory reviews and emerge intact, even though investors are nervous about its chances.

In Asia however, tough regulatory regimes, cumbersome ownership structures and protectionist-minded governments mean cross-border mergers involving regional markets will be difficult.

Jeff Carter at Points and Figures looks for the synergies in the Deutsche Boerse/NYSE deal.

China’s new review body for inward M&A could bring some much-needed transparency to the deal approval process and even make it quicker for foreign companies to get tie-ups with mainland firms past the authorities.

Post Your Comment

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/